Archus Orthopedics
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/DePuy Spine makes the principal investment in the Redmond, Wash. firm's $35 mil. Series C financing round closed Jan. 18, establishing "a framework for future collaboration between Archus and DePuy," according to Archus. FDA granted an investigational device exemption in March for the company's Total Facet Arthroplasty System as a mobility-preserving alternative to spinal fusion following back surgery performed on patients with facet degeneration (1"The Gray Sheet" April 4, 2005, p. 19). Archus has said it will not likely launch the product in the U.S. or Europe, where it already has a CE Mark, without corporate partnership...